Powering digital-first clinical research
The Evidence for Decentralized Clinical Trials
Since their creation in the 1940s, Randomised Controlled Trials (RCTs) have been the go-to method for treatment evaluations.
However, the traditional approach to these trials can slow down the research process. The DeTAP study, conducted by the Stanford School of Medicine in partnership with Bayer and Huma, showcased the immense potential of decentralized clinical trials (DCTs).
By adopting a digital-first approach, the study achieved high engagement, rapid recruitment, and increased medication adherence in patients with low baseline.
Read our whitepaper below to uncover the results of one of the first peer-reviewed assessments of a fully decentralized clinical trial:
Ready. Set. Go.
Streamlined user journeys help accelerate time to “first patient in” and get your trial up and running with minimal fuss. Our fully integrated screening and consent workflows enable quicker, easier setup and enrollment.
With less time spent on logistics, you’re free to focus on what’s truly at the heart of your clinical study: your participants.
Engaging. Efficient. Clinically proven.
Huma’s award-winning human-centered design has been developed with an understanding of the complex needs of patients and clinicians in mind, enabling us to impact each touchpoint across clinical trial phases. Now you can enroll participants faster and keep them engaged longer for better clinical trial outcomes.
Regulatory, safety and compliance
MHRA registered Medical Device Class IIb
US Food and Drug Administration Medical Device 510k # K230214
ISO 13485: 2016 certified (Medical Devices: Quality Management Systems)
ISO 27001: 2013 certified
Committed to GDPR compliance
NHS Registration on Data Security and Protection Toolkit
CyberEssentials / CyberEssentials Plus